Unicentric real-world data from esophageal cancer neoadjuvant treatment according to the CROSS trial protocol

被引：0
|
作者：
Mendonca, J. [1 ]
Silva, C. [2 ]
Calcada, C. [2 ]
Fardilha, C. [2 ]
Gagean, J. [2 ]
Costa, P. [2 ]
机构：
[1] Hosp Senhora de Oliveira, Guimaraes, Portugal
[2] Hosp Braga, Braga, Portugal
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-94
引用
收藏
页码：S129 / S130
页数：2
相关论文
共 50 条
  • [1] Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
    Amrith, B. P.
    Sharma, M.
    Singh, H.
    Koyyala, V. P. B.
    Joga, S.
    Batra, U.
    ANNALS OF ONCOLOGY, 2022, 33 : S1479 - S1480
  • [2] A real-world clinical study of camrelizumab in the treatment of esophageal cancer
    Sun, G.
    Peng, W.
    Wang, F.
    Cheng, H.
    Wang, S. Z.
    Xia, L.
    Du, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1318 - S1318
  • [3] Real-World or Controlled Clinical Trial Data in Real-World Practice
    Wu, Ting-Hui
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 470 - 472
  • [4] Real-world study: from real-world data to real-world evidence
    Wen, Yi
    TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
  • [5] Real-world data: Correlation of radiological and pathologic complete response after neoadjuvant treatment of breast cancer
    Cular, K.
    Gudelj, D.
    Toula, L.
    Krizic, M.
    Soce, M.
    Plavetic, N. Dedic
    Popovic, M.
    Silovski, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S317 - S317
  • [6] A real-world clinical study of camrelizumab in the treatment of esophageal cancer.
    Sun, Guoping
    Qian, Dong
    Zhao, Dong
    Liang, Hui
    Cheng, Huaidong
    Wang, Genhe
    Wang, Fan
    Jiang, Hao
    Xu, Tengyun
    Wu, Qibing
    Zhu, Shaojin
    Xu, Dong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Neoadjuvant chemoradiation (NCRT) for esophageal (EC) or gastroesophageal junction cancer (GEJC): A Canadian single institution real-world experience using the CROSS trial regimen.
    Khalid, Sidra
    Hopman, Wilma M.
    Preti, Beatrice
    Tomiak, Anna T.
    Virik, Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [8] Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China
    Yang, Yang
    Tan, Lijie
    Hu, Jian
    Li, Yin
    Mao, Yousheng
    Tian, Ziqiang
    Zhang, Baihua
    Ma, Jianqun
    Li, Hecheng
    Chen, Chun
    Chen, Keneng
    Han, Yongtao
    Chen, Longqi
    Liu, Junfeng
    Yu, Bentong
    Yu, Zhentao
    Li, Zhigang
    DISEASES OF THE ESOPHAGUS, 2022, 35 (11)
  • [9] Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis
    Zhang, Yao
    Li, Huiting
    Yu, Bo
    Sun, Si
    Hu, Zhihuang
    Wu, Xianghua
    Zhang, Yang
    Li, Bin
    Zhang, Yawei
    Xiang, Jiaqing
    Wang, Jialei
    Yu, Hui
    THORACIC CANCER, 2024, 15 (13) : 1072 - 1081
  • [10] Editorial: Real-world data and real-world evidence in lung cancer
    Gristina, Valerio
    Eze, Chukwuka
    FRONTIERS IN ONCOLOGY, 2024, 14
12345